Neo or Not Neo? Widefield OCT-A Reveals Hidden Neovascularization

• by Julie Rodman, OD, MSc, FAAO

• March 2, 2026

Could Wegovy Raise Optic Nerve Risk?

A pharmacovigilance analysis of FDA adverse event reports finds the strongest ischemic optic neuropathy reporting signal with high-dose semaglutide formulations, with higher adjusted odds reported in men.

• by Kerri Miller

• March 11, 2026

• 5 min

DME AWARE Study Defines Key Needs

Presenting results from the DME AWARE Delphi Study at the Association for Research in Vision and Ophthalmology (ARVO) meeting in Denver, Baruch D. Kuppermann, MD, PhD, director of the Gavin Herbert Eye Institute at the University of California, Irvine, described a set of consensus findings that point to unmet needs across the continuum of DME management, with particular emphasis on early intervention and noninvasive treatment options (Figure 1).

• by Jim Gallagher, senior managing editor

• May 1, 2026

• 5 min

Suprachoroidal Injection in the Treatment of Diabetic Macular Edema: Mechanisms, Clinical Advances, and Future Perspectives

• by Chen, Menghan , Jiao, Wanzhen , Liu, Tianwei , Zhao, Bojun

• April 16, 2026